{"nctId":"NCT00792805","briefTitle":"Efficacy and Safety of Indacaterol in Adults (40 Years and Above) With Chronic Obstructive Pulmonary Disease (COPD)","startDateStruct":{"date":"2008-11"},"conditions":["Chronic Obstructive Pulmonary Disease (COPD)"],"count":563,"armGroups":[{"label":"Indacaterol 150 μg","type":"EXPERIMENTAL","interventionNames":["Drug: Indacaterol 150 µg"]},{"label":"Indacaterol 300 μg","type":"EXPERIMENTAL","interventionNames":["Drug: Indacaterol 300 μg"]},{"label":"Placebo to indacaterol","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo to indacaterol"]}],"interventions":[{"name":"Indacaterol 150 µg","otherNames":[]},{"name":"Indacaterol 300 μg","otherNames":[]},{"name":"Placebo to indacaterol","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Adults aged ≥ 40 years\n* Diagnosis of chronic obstructive pulmonary disease (COPD) (moderate to severe as classified by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines, 2007) and:\n\n  1. Smoking history of at least 10 pack years\n  2. Post-bronchodilator forced expiratory volume in 1 second (FEV1) \\< 80% and ≥ 30% of the predicted normal value\n  3. Post-bronchodilator FEV1/FVC (forced vital capacity) \\< 70%\n\nExclusion Criteria:\n\n* Patients who have received systemic corticosteroids for a COPD exacerbation in the 6 weeks prior to screening or during the run-in period\n* Patients requiring long-term oxygen therapy (\\> 15 hours a day) for chronic hypoxemia\n* Patients who have had a respiratory tract infection within 6 weeks prior to screening\n* Patients with concomitant pulmonary disease\n* Patients with a history of asthma\n* Patients with diabetes Type I or uncontrolled diabetes Type II\n* Any patient with lung cancer or a history of lung cancer\n* Any patient with active cancer or a history of cancer with less than 5 years disease-free survival time\n* Patients with a history of long QT syndrome or whose QTc interval (Bazett's) measured at screening is prolonged\n* Patients who have been vaccinated with live attenuated vaccines within 30 days prior to screening or during the run-in period\n* Patients unable to successfully use a dry powder inhaler device or perform spirometry measurements\n\nOther protocol-defined inclusion/exclusion criteria applied to the study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12 + 1 Day, Day 85","description":"FEV1 was measured with spirometry conducted according to internationally accepted standards. Trough FEV1 was defined as the average of measurements made 23 hours 10 minutes and 23 hours 45 minutes post-dose at the end of treatment. The analysis included baseline FEV1 and FEV1 pre-dose and 10-15 minutes post-dose of salbutamol/albuterol during screening as covariates.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.32","spread":"0.024"},{"groupId":"OG001","value":"1.29","spread":"0.024"},{"groupId":"OG002","value":"1.17","spread":"0.024"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":12,"n":187},"commonTop":["Chronic obstructive pulmonary disease","Upper respiratory tract infection","Nasopharyngitis"]}}}